Tango Therapeutics, Inc.
TNGX
$10.08
-$0.34-3.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 363.61% | -83.99% | -16.67% | -24.19% | 8.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 363.61% | -83.99% | -16.67% | -24.19% | 8.15% |
| Cost of Revenue | -7.36% | -15.13% | -4.26% | 8.29% | 22.52% |
| Gross Profit | 206.19% | -57.76% | 1.72% | -15.10% | -31.91% |
| SG&A Expenses | -20.48% | 5.27% | 7.68% | 21.80% | 21.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.67% | -10.68% | -1.65% | 11.33% | 22.35% |
| Operating Income | 142.80% | -38.63% | -0.65% | -16.84% | -28.30% |
| Income Before Tax | 154.53% | -52.31% | -5.20% | -22.48% | -30.90% |
| Income Tax Expenses | -118.52% | -46.15% | -15.00% | 4.26% | 134.78% |
| Earnings from Continuing Operations | 154.46% | -52.06% | -5.17% | -22.45% | -31.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.46% | -52.06% | -5.17% | -22.45% | -31.01% |
| EBIT | 142.80% | -38.63% | -0.65% | -16.84% | -28.30% |
| EBITDA | 145.35% | -39.50% | -0.67% | -17.14% | -28.96% |
| EPS Basic | 153.24% | -49.00% | -3.14% | -9.54% | -17.18% |
| Normalized Basic EPS | 153.31% | -49.22% | -1.15% | -2.04% | -17.11% |
| EPS Diluted | 148.15% | -49.00% | -3.14% | -9.54% | -17.70% |
| Normalized Diluted EPS | 150.21% | -49.22% | -1.15% | -2.04% | -17.11% |
| Average Basic Shares Outstanding | 2.27% | 2.06% | 1.97% | 11.79% | 11.82% |
| Average Diluted Shares Outstanding | 8.55% | 2.06% | 1.97% | 11.79% | 11.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |